Four pillars of heart failure: contemporary pharmacological therapy for heart failure with reduced ejection fraction
HOW DID WE GET HERE? Heart failure guidelines are based around inhibition of the renin-
angiotensin and sympathetic nervous systems, two fundamental pathways which drive the …
angiotensin and sympathetic nervous systems, two fundamental pathways which drive the …
Review of the National Institute for Health and Care Excellence guidelines on chronic heart failure
DJ Doherty, KF Docherty, RS Gardner - Heart, 2024 - heart.bmj.com
Guidelines are more accessible than ever and represent an important tool in clinical
practice. The National Institute for Health and Care Excellence (NICE) has developed …
practice. The National Institute for Health and Care Excellence (NICE) has developed …
Pharmacotherapy sequencing strategies for patients with heart failure with reduced ejection fraction: a cost–utility analysis
Background Standard pharmacotherapy for patients with heart failure with reduced ejection
fraction (HFrEF) comprises “quadruple therapy” with a renin–angiotensin system inhibitor, a …
fraction (HFrEF) comprises “quadruple therapy” with a renin–angiotensin system inhibitor, a …
Disproportionate secondary mitral regurgitation: myths, misconceptions and clinical implications
Secondary (functional) mitral regurgitation (SMR) most commonly arises secondary to left
ventricular (LV) dilation/dysfunction. The concept of disproportionately severe SMR was …
ventricular (LV) dilation/dysfunction. The concept of disproportionately severe SMR was …
Temporal trends in heart failure medication prescription in a population-based cohort study
A Uijl, I Vaartjes, S Denaxas, H Hemingway, A Shah… - BMJ open, 2021 - bmjopen.bmj.com
Objective We examined temporal heart failure (HF) prescription patterns in a large
representative sample of real-world patients in the UK, using electronic health records …
representative sample of real-world patients in the UK, using electronic health records …
Rationale and protocol of the LAQUA-HF trial: a factorial randomised controlled trial evaluating the effects of neurohormonal and diuretic agents on health-status …
Introduction The current guidelines strongly recommend early initiation of multiple classes of
cardioprotective drugs for patients with heart failure with reduced ejection fraction to improve …
cardioprotective drugs for patients with heart failure with reduced ejection fraction to improve …
impHFrEF trial: study protocol for an open-label, multicentre study of improvement the outcome of patients with heart failure in China using a mobile hEalth-supported …
F Chen, G Li, X Zhang, Q Shen, F Wang, X Dong… - BMJ open, 2024 - bmjopen.bmj.com
Background Patients with chronic heart failure (CHF) often have a long duration of illness,
difficulty in attending follow-up visits, and poor adherence to treatment. As a result, they …
difficulty in attending follow-up visits, and poor adherence to treatment. As a result, they …
Sequencing of medical therapy in heart failure with a reduced ejection fraction
HO Savage, AD Dimarco, B Li, S Langley… - Heart, 2023 - heart.bmj.com
The management of heart failure with a reduced ejection fraction is a true success story of
modern medicine. Evidence from randomised clinical trials provides the basis for an …
modern medicine. Evidence from randomised clinical trials provides the basis for an …
PRospective Evaluation of natriuretic peptide-based reFERral of patients with chronic heart failure in primary care (PREFER): a real-world study
FDR Hobbs, RI Hussain, C Vitale, YM Pinto… - Open …, 2021 - openheart.bmj.com
Objective To assess current management practice of heart failure with reduced ejection
fraction (HFrEF) in multinational primary care (PC) and determine whether N-terminal-pro-B …
fraction (HFrEF) in multinational primary care (PC) and determine whether N-terminal-pro-B …
Beta-Blocker Usage in Patients With Heart Failure With Reduced Ejection Fraction During Acute Decompensated Heart Failure Hospitalizations
Background: Acute decompensated heart failure accounts for more than 1 million
hospitalizations in the United States every year. Beta-blockers are a first-line agent for …
hospitalizations in the United States every year. Beta-blockers are a first-line agent for …